| INTRODUCTION
Barrett's oesophagus (BO) is characterised by the replacement of squamous epithelium in the oesophagus with specialised intestinal metaplasia and remains the strongest risk factor for oesophageal adenocarcinoma (OAC). 1 Acid suppressive medications such as proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) are commonly used medications to control gastro-oesophageal reflux symptoms, with some recent data suggesting their use being associated with lower risk of progression to OAC. 2 Patients with BO are often treated with higher doses of PPIs for more prolonged periods than other patients with gastrooesophageal reflux disease given the known greater severity of reflux in BO compared to erosive and non-erosive reflux disease and the need to ensure tight reflux control during and after ablative therapy. 3 Although several studies examining the association between acid inhibition and hip fractures exist, the results have frequently been discordant. [4] [5] [6] [7] [8] [9] [10] [11] [12] A case-control study using the UK General Practice Database found an increased fracture risk among persons taking acid inhibitors (both PPI and H2RA) for more than 1 year, even after adjustment for multiple confounders. 4 However, a nested case-control study using the same database, restricted to persons without risk factors for hip fracture, found no association between PPI and fracture risk. 5 Another study reported an increased risk of fracture with even short durations (<1 year) of acid inhibitor (PPI or H2RA) use. 6 A Canadian study, found elevated risk only after more than 6 years of use 7 In contrast to other studies, which did not report an increased risk of fragility fractures with PPI use. 8, 9 Finally, while some meta-analyses have reported an increased incidence of hip and vertebral fractures with PPI use, the absence of randomised controlled studies included in those analyses weakens conclusions that can be drawn. [10] [11] [12] Putative mechanisms by which PPI might affect skeletal integrity include altered bone remodelling by modulating the activity of acid-related enzymes at the level of the osteoclast, thereby affecting fracture risk. 13, 14 Alternatively, it has been suggested that prolonged PPI use results in decreased intestinal calcium absorption and negative overall body calcium balance, ultimately leading to secondary hyperparathyroidism, skeletal calcium losses and increased fracture risk. [15] [16] [17] Patients with BO represent a unique population for studying the association between PPI use and osteoporosis-related fractures, due to their treatment with long-term and high-dose acid suppressive therapy with PPIs to control reflux. However, there are no data on the incidence of low bone mass (osteoporosis and/or osteopenia) related fractures in this population. We therefore performed a nested case-control study to determine the incidence of low bone mass and related fractures in patients with BO and to compare this incidence to that of the general population. We also performed additional analyses to assess predictors of osteoporotic fractures in this cohort. sted County, who obtain medical care through these facilities. 18 The availability of a centralised index to access patient medical records makes this database well suited for conducting population-based disease observational studies.
| MATERIALS AND METHODS

| The Rochester Epidemiology Project
19,20
| Subject identification and data abstraction
The Institutional Review Boards of Mayo Clinic and Olmsted Medical
Center approved this study.
| Search strategies and characteristics of the
Barrett's oesophagus cohort
Patients who had BO diagnosed between 1989 and 2013 formed our study cohort. These subjects were identified using REP resources as previously described. 19 This included an electronic search of the REP database followed by chart review of electronic and paper medical records of identified patients. We chose to include BO patients diagnosed from 1989 as this coincides approximately with the introduction of PPI therapy for the treatment of acid reflux disease. 21 For the electronic medical records search, we utilised the International Classification of Diseases, 9th version (ICD-9)/Hospital Adaptation of the International Classification of Disease-A (HICDA) coding systems. The electronic search codes utilised for identifying BO, osteoporosis, osteopenia and fracture(s) are included in Appendix S1.
Medical records of all identified subjects were then examined for confirmation of reported diagnoses and to obtain additional clinical data.
Electronic and paper medical records of all study subjects were reviewed for demographic details, office visit records, oesophagogastroduodenoscopy notes, and laboratory and pathology reports as available. The age and severity weighted Charlson comorbidity index was used to assess comorbidity. 22 26 An osteoporotic fracture (fragility fracture) was defined as a non-pathologic, non-incidental moderate trauma fracture at one or more sites, where such a fracture would be frequently expected to occur (such as hip, thoracic or lumbar vertebrae, wrist or distal forearm).
| Nested case: control study design
All patients with BO who were diagnosed with low bone mass and/ or osteoporotic fracture after the BO diagnosis (cases) were compared with patients within the cohort who did not develop low bone mass and/or osteoporotic fracture (controls).
| Statistical analyses
The primary analysis compared the number of fractures observed at each skeletal site (based on the first fracture of a given type per person) to the number expected in the cohort during follow-up in the community, that is, standardised incidence ratios (SIRs). Expected numbers were derived by applying local calendar year-, age-and sex-specific incidence rates for fractures to the calendar year-and age-specific person-years of follow-up in the BO cohort and summing over the strata. This has been previously reported. Charlson comorbidity index, corticosteroid use, smoking history and PPI use were assessed using Cox proportional hazard models.
3 | RESULTS
| Study cohort
Five hundred eighty-five patients were diagnosed with BO during the period from 1989 to 2013, of which 14 patients were excluded as they had declined to authorise use of their medical records for research. Of the remaining 571 patients whose records were reviewed, 50 patients were excluded from further analyses due to either a diagnosis of low bone mass or an osteoporotic fracture prior to BO diagnosis. Hence, our final study cohort was composed of 521 patients.
| Clinical characteristics
Clinical characteristics for BO patients (with and without low bone mass and fractures) are outlined in and hip (20 fractures) (detailed in Table 2 ). Eight fractures (5.2%)
resulted from a specific pathologic lesion (in the axial skeleton due to metastatic malignancy). The aetiology of the remaining three (2%) fractures was uncertain. Highest fracture occurrence rates were observed at the level of thoracic/lumbar vertebrae (17.8%) followed by other lower extremity (16.4%) and proximal femur (14.5%).
| Incidence ratios of fractures and osteoporotic fractures
The relative risk (RR) of fracture occurrence by skeletal site and immediate cause is shown in Table 3 . While statistically significant incidence ratios were not observed for fractures at any specific site (such as hip, vertebrae, wrist or ribs), the highest numerical risk was 
| Predictors of osteoporosis and/or fracture occurrence in the cohort
Potential risk factors for osteoporotic fracture occurrence are outlined in Tables 4 and 5 . Specifically, PPI use in our study cohort was not associated with a statistically significant risk for developing an osteoporotic fracture at any site (HR 0.89; 95% CI 0.12-6.55). The duration and dosing regimen of PPI use (once daily vs twice daily)
were also found not to be associated with increased osteoporotic fracture risk (HR 0.96; 95% CI 0.89-1.02: HR 0.49; 95% CI 0.21-
1.16).
Variables previously shown to be associated with osteoporotic fractures such as female gender and older age were significantly associated with the occurrence of these fractures (female gender P = .005; older age P < .001), while a history of corticosteroid use showed a trend towards statistical significance (P = .05). In addition, a higher
Charlson comorbidity index at the time of diagnosis of BO was associated with increased fracture risk (P < .001). Reported P values were estimated from univariate Cox proportional Hazard models.
| DISCUSSION
In this large population-based cohort of patients of BO, we demonstrate that the overall risk of any fracture was not elevated when compared to the reference (age and gender matched) population in Olmsted County, Minnesota. However, these associations have been reported in the presence of at least one other risk factor for osteoporosis. [5] [6] [7] Indeed, in our study predictors of an osteoporotic fracture included some wellknown risk factors such as older age, female gender and a higher co-morbidity score, which may reflect a more fragile medical state, as reported by other investigators. 8 In contrast to other studies, we did not observe an increased risk of osteoporotic fractures in BO patients treated with chronic PPIs (HR 0.89; CI 0.12-6.55). Compared to studies from administrative databases, our study is not only population based, but allows both initial case ascertainment using diagnostic codes and subsequent verification by access to linked medical records to confirm or refute these diagnoses, due to the resources available via the REP, making the results of the study more robust. In addition, given the availability of fracture rates in the general population of Olmsted County, 31, 32 we were able calculate SIRs, which are not available in other population-based studies given lack of expected incidence at a population level. The substantially longer and complete follow-up available in the subjects of this study (almost 8 years) is an additional strength of this study, which makes its results more reliable.
The duration of use of PPI also seemed to have some role in association with fracture occurrence with most studies generally demonstrating increased risk with longer durations of use. [5] [6] [7] In our study, the duration of use of PPI was not associated with increased Our study has a number of strengths. This is the first study to assess the incidence of low bone mass related fractures in patients with BO, which is an important population to study, since nearly all these patients are maintained on long-term, high-dose PPI therapy.
During chart review, fractures were confirmed in the medical records spanning each subject's entire period of residency in the community.
Since most fractures come to medical attention, ascertainment should be nearly complete, with the possible exception of incidentally detected vertebral fractures.
There are also potential limitations to studies that use medical records. One potential limitation may be the generalisability of these shown to be comparable to that of the US Caucasian population generally. 32 In addition, BO affects Caucasians at a higher rate than other ethnic groups. In addition, since measurements of bone mineral density were not routinely performed in all patients, the contribution of bone loss to fracture risk could not be evaluated directly. However, this was somewhat mitigated by using an accepted clinical definition of osteoporotic fractures which allows fractures to be classified as osteoporotic even in the absence of documented reduced bone density by a DXA scan. Given that incidence rates for osteoporosis and osteopenia are not available for the Olmsted County population, we were unable to estimate SIRs for osteoporosis or osteopenia in our cohort. Furthermore, osteoporosis and/or osteopenia may be clinically silent in individuals, thereby requiring a screening, DXA scan in everyone to be able to ascertain the true incidence rates of low bone mass in the general population. Finally, the presence of confounding factors, both identified and unidentified, limit the ability of an observational study such as this to determine causality.
In conclusion, while fractures (both osteoporotic and from any aetiology) are not uncommon in subjects with BO, their incidence is not increased when compared to that of the general population. In T A B L E 3 Observed and expected numbers of all fractures and osteoporotic fractures in Barrett's oesophagus subjects and respective standardised incidence ratios (SIR) The number of fractures observed at specific skeletal sites may differ from those reported in Table 3 because only the first fracture of each type per patient was counted in this analysis. addition, PPI use in patients with BO was not associated with an increased osteoporotic fracture risk when compared to the general population regardless of the duration of use and dosing strategy. 
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